Extendicare Inc.
Extendicare Inc. (EXETF) Financial Performance & Income Statement Overview
Analyze Extendicare Inc. (EXETF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Extendicare Inc. (EXETF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Extendicare Inc. EXETF financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $374.65M | $391.56M | $359.06M | $348.48M |
| Cost of Revenue | $0.00 | $346.44M | $0.00 | $295.68M |
| Gross Profit | $374.65M | $45.12M | $359.06M | $52.81M |
| Gross Profit Ratio | $1.00 | $0.12 | $1.00 | $0.15 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $309.79M | $316.37M | $293.73M | $14.20M |
| Operating Expenses | $347.32M | $14.12M | $331.59M | $14.20M |
| Total Costs & Expenses | $347.32M | $360.36M | $331.59M | $309.87M |
| Interest Income | $1.38M | $1.80M | $1.86M | $1.92M |
| Interest Expense | $4.21M | $4.91M | $5.02M | $5.23M |
| Depreciation & Amortization | $8.27M | $8.70M | $8.63M | $8.25M |
| EBITDA | $31.99M | $40.22M | $36.62M | $46.11M |
| EBITDA Ratio | $0.09 | $0.10 | $0.10 | $0.13 |
| Operating Income | $27.33M | $31.20M | $27.47M | $38.61M |
| Operating Income Ratio | $0.07 | $0.08 | $0.08 | $0.11 |
| Other Income/Expenses (Net) | -$8.41M | -$4.48M | -$4.82M | -$5.72M |
| Income Before Tax | $18.92M | $26.72M | $22.66M | $32.89M |
| Income Before Tax Ratio | $0.05 | $0.07 | $0.06 | $0.09 |
| Income Tax Expense | $3.89M | $6.79M | $6.36M | $7.002M |
| Net Income | $15.03M | $19.93M | $16.30M | $25.89M |
| Net Income Ratio | $0.04 | $0.05 | $0.05 | $0.07 |
| EPS | $0.18 | $0.32 | $0.20 | $0.30 |
| Diluted EPS | $0.18 | $0.28 | $0.19 | $0.27 |
| Weighted Avg Shares Outstanding | $84.44M | $84.27M | $81.47M | $86.30M |
| Weighted Avg Shares Outstanding (Diluted) | $85.40M | $94.08M | $85.76M | $95.25M |
Over the past four quarters, Extendicare Inc. demonstrated steady revenue growth, increasing from $348.48M in Q2 2024 to $374.65M in Q1 2025. Operating income reached $27.33M in Q1 2025, maintaining a consistent 7% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $31.99M, reflecting operational efficiency. Net income dropped to $15.03M, with EPS at $0.18. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan